# Nuclide record nct06590857 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct06590857/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct06590857", "NCT06590857" ;
  schema:name "Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs."@en ;
  schema:alternateName "TRACY-1"@en ;
  schema:description "A phase 1/2 trial of Actinium-225 DOTATATE in HR-positive / HER2-negative breast cancer, run by RayzeBio, Inc., active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct06590857/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06590857> ;
  nuclide:status "active" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:phase "1/2" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:drugs <https://nuclide.cc/drugs/ryz101/> ;
  nuclide:companies <https://nuclide.cc/companies/rayzebio/> .